James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.

Advertisement

Advertisement

Advertisement